(0.10%) 5 105.01 points
(0.22%) 38 324 points
(0.15%) 15 952 points
(-1.30%) $82.76
(6.50%) $2.05
(-0.09%) $2 345.00
(-0.27%) $27.46
(3.94%) $958.45
(-0.21%) $0.933
(-0.35%) $10.99
(-0.53%) $0.796
(1.66%) $93.40
2 days till quarter result
(bmo 2024-05-01)
Expected move: +/- 8.94%
@ $49.09
发出时间: 14 Feb 2024 @ 22:30
回报率: 14.77%
上一信号: Feb 10 - 04:40
上一信号:
回报率: -2.06 %
Live Chart Being Loaded With Signals
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support...
Stats | |
---|---|
今日成交量 | 529 368 |
平均成交量 | 671 158 |
市值 | 3.04B |
EPS | $0 ( 2024-02-21 ) |
下一个收益日期 | ( $0.450 ) 2024-05-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 176.06 |
ATR14 | $0.0600 (0.11%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-30 | Bolton Stephanie | Buy | 7 744 | Ordinary Shares |
2024-03-30 | Bolton Stephanie | Buy | 10 746 | Stock Appreciation Rights |
2024-03-30 | Bolton Stephanie | Sell | 3 643 | Ordinary Shares |
2024-03-30 | Bolton Stephanie | Buy | 4 915 | Restricted Stock Units |
2024-03-30 | Bolton Stephanie | Buy | 4 915 | Performance Stock Units |
INSIDER POWER |
---|
50.90 |
Last 100 transactions |
Buy: 371 593 | Sell: 126 373 |
音量 相关性
LivaNova PLC 相关性 - 货币/商品
LivaNova PLC 财务报表
Annual | 2023 |
营收: | $1.15B |
毛利润: | $785.45M (68.09 %) |
EPS: | $0.330 |
FY | 2023 |
营收: | $1.15B |
毛利润: | $785.45M (68.09 %) |
EPS: | $0.330 |
FY | 2022 |
营收: | $1.02B |
毛利润: | $707.20M (69.21 %) |
EPS: | $-1.610 |
FY | 2021 |
营收: | $1.04B |
毛利润: | $705.99M (68.19 %) |
EPS: | $-2.68 |
Financial Reports:
No articles found.
LivaNova PLC
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。